
The study comes from the Substance Abuse and Mental Health Services Administration (SAMHSA) and is based on the findings by the Drug Abuse Warning Network (DAWN). DAWN monitors incidents of mortality or drug related morbidity across the nation. In January 2013, the FDA required that the manufacturer of Ambien halve the recommended dose for women because the drowsiness effect often lasted more than 12 hours. The agency only mentioned possibly reducing the dose for men.

Split by gender, zolpiden emergency visits increased 150 percent for men and 69 percent for women. Other prescription drugs were implicated in 57 percent of the visits regarding zolpiden. 26 percent of the incidents involved benzodiazepines and 25 percent involved narcotics.
This study highlights the dangers of prescription sleep aids and the lack of necessary education and guidance on the use of them. While zolpiden is accepted as a treatment for short term insomnia, its dangers can often be understated. It is the job of both the manufacturer and the medical service provider to make sure that patients understand the risks of prescribed medications. When the dangers of a medication are not adequately communicated to the consumer, patients may suffer serious injuries.
Lopez McHugh’s pharmaceutical lawyers are experienced in handling both medical malpractice and pharmaceutical lawsuits. If you or a loved one suffered an injury as a result of poorly or overprescribed medication or insufficient risk analysis, contact us today at (877) 737-8525 or fill out a contact form on our website for a free initial case evaluation.
